BeiGene
BGNE
#881
Rank
โ‚น1.860 T
Marketcap
โ‚น16,946
Share price
1.71%
Change (1 day)
5.70%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -โ‚น73.82 B

According to BeiGene 's latest financial reports the company's current earnings (TTM) are -โ‚น74.36 B. In 2023 the company made an earning of -โ‚น101.33 B an increase over its 2022 earnings that were of -โ‚น150.15 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -โ‚น73.82 B-27.14%
2023 -โ‚น101.33 B-32.52%
2022 -โ‚น150.15 B24.39%
2021 -โ‚น120.71 B-13.21%
2020 -โ‚น139.07 B72.69%
2019 -โ‚น80.53 B36.01%
2018 -โ‚น59.21 B616.83%
2017 -โ‚น8.26 B-15.24%
2016 -โ‚น9.75 B107.91%
2015 -โ‚น4.69 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚น1.53 B-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น20.53 B-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA